Venbio Partners LLC

Investment Portfolio & 13F Holdings Analysis

About

Type: FundHoldings: 7Value: $123.6MLatest: 2025Q1

venBio Partners LLC is an institutional investment manager that filed its latest Form 13F for 2025Q1, reporting 7 holdings worth $0.1 billion. Form 13F filings provide transparency into the equity holdings of institutional investment managers with over $100 million in assets under management. This page displays the most recent portfolio holdings, allowing investors to track position changes, new investments, and portfolio composition.

AI_NATIVE detailed information: This accession holds the following tickers:[
  "ALXO",
  "SLRN",
  "PHVS",
  "ALMS",
  "ARTV",
  "LYEL",
  "HRMY"
]

Filing Details

13F-HR • 2025-03-31

SEC FilingSEC DataHachi Filing

Report Date: 2025-03-31
Filing Date: 2025-05-15
Total Holdings: 7
Total Value: 123555835
Accession Number: 0000905148-25-001748
Form Type: 13F-HR
CIK: venbio-partners
Manager Name: Venbio-Partners

Data Enrichment

100% identified

7 identified0 unidentified

Holdings

SEC FilingSEC DataHachi Filing

Manager:

7 positions • $123.6M total value

SEC FilingSEC DataHachi Filing

Manager:

Search and click to pin securities to the top

Sort by:

Pharvaris N.V.

PHVS|N69605108

Shares:4.3M

Value:$67.3M

% of Portfolio:54.5% ($67.3M/$123.6M)

ALUMIS INC.

ALMS|022307102

Shares:2.8M

Value:$17.1M

% of Portfolio:13.9% ($17.1M/$123.6M)

Harmony Biosciences Holdings, Inc.

HRMY|413197104

Shares:489.2K

Value:$16.2M

% of Portfolio:13.1% ($16.2M/$123.6M)

ACELYRIN, Inc.

SLRN|00445A100

Shares:3.8M

Value:$9.4M

% of Portfolio:7.6% ($9.4M/$123.6M)

ALX ONCOLOGY HOLDINGS INC

ALXO|00166B105

Shares:9.7M

Value:$6.0M

% of Portfolio:4.9% ($6.0M/$123.6M)

Lyell Immunopharma, Inc.

LYEL|55083R104

Shares:7.1M

Value:$3.8M

% of Portfolio:3.1% ($3.8M/$123.6M)

Artiva Biotherapeutics, Inc.

ARTV|04317A107

Shares:1.2M

Value:$3.6M

% of Portfolio:2.9% ($3.6M/$123.6M)

Instrument	Shares		Other Manager	Value	% of Portfolio
Pharvaris N.V.(PHVScusipN69605108)	4.3M	QoQ 0.00% (-0) YoY 0.00% (-0)	All Managers (Combined)	$67.3M	54.5% ($67.3M/$123.6M)	QoQ -18.10% (-$14.9M) YoY -32.06% (-$31.8M)
ALUMIS INC.(ALMScusip022307102)	2.8M	QoQ 0.00% (-0) YoY NEW(+2.8M)	All Managers (Combined)	$17.1M	13.9% ($17.1M/$123.6M)	QoQ -21.88% (-$4.8M) YoY NEW(+$17.1M)
Harmony Biosciences Holdings, Inc.(HRMYcusip413197104)	489.2K	QoQ -9.27% (-50.0K) YoY -52.75% (-546.2K)	All Managers (Combined)	$16.2M	13.1% ($16.2M/$123.6M)	QoQ -12.48% (-$2.3M) YoY -53.30% (-$18.5M)
ACELYRIN, Inc.(SLRNcusip00445A100)	3.8M	QoQ 0.00% (-0) YoY -1.19% (-46.1K)	All Managers (Combined)	$9.4M	7.6% ($9.4M/$123.6M)	QoQ -21.33% (-$2.6M) YoY -63.84% (-$16.6M)
ALX ONCOLOGY HOLDINGS INC(ALXOcusip00166B105)	9.7M	QoQ 0.00% (-0) YoY 0.00% (-0)	All Managers (Combined)	$6.0M	4.9% ($6.0M/$123.6M)	QoQ -62.69% (-$10.2M) YoY -94.41% (-$102.1M)
Lyell Immunopharma, Inc.(LYELcusip55083R104)	7.1M	QoQ 0.00% (-0) YoY NEW(+7.1M)	All Managers (Combined)	$3.8M	3.1% ($3.8M/$123.6M)	QoQ -15.93% (-$724.4K) YoY NEW(+$3.8M)
Artiva Biotherapeutics, Inc.(ARTVcusip04317A107)	1.2M	QoQ -21.11% (-321.0K) YoY NEW(+1.2M)	All Managers (Combined)	$3.6M	2.9% ($3.6M/$123.6M)	QoQ -76.52% (-$11.7M) YoY NEW(+$3.6M)